Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | APAF1 | O14727 | 1/20 | 0.52 |
| ▸ | MITF | O75030 | 1/20 | 0.52 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | TERT | O14746 | 4/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL375141 | 0.95 | TDP1 (0.51) | TDP1APAF1MITFP2RY4MAPT | |
| SCHEMBL9309333 | 0.88 | MAPT (0.51) | TDP1APAF1MITFP2RY4MAPT | |
| SCHEMBL3975751 | 0.87 | P2RY4 (0.62) | TDP1APAF1MITFP2RY4MAPT | |
| SCHEMBL9309180 | 0.85 | MAPT (0.49) | TDP1P2RY4MAPTMAPK1RAB9A | |
| SCHEMBL9308563 | 0.84 | MAPT (0.48) | TDP1P2RY4MAPTMAPK1RAB9A | |
| SCHEMBL10938974 | 0.83 | MAPT (0.44) | TDP1APAF1MITFP2RY4MAPT | |
| SCHEMBL11496174 | 0.82 | P2RY4 (0.47) | TDP1APAF1MITFP2RY4MAPT | |
| SCHEMBL13893952 | 0.82 | P2RY4 (0.57) | TDP1APAF1MITFP2RY4MAPT | |
| SCHEMBL1476567 | 0.82 | MAPT (0.52) | TDP1P2RY4MAPTMAPK1RAB9A | |
| SCHEMBL10727142 | 0.82 | MAPT (0.52) | TDP1APAF1MITFP2RY4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1538154-B1 | Quencher composition comprising anthraquinone moieties | EXIQON AS (DK) | 2008-12-31 | — | — | EP | claimed |
| EP-1831394-A2 | PROBES, LIBRARIES AND KITS FOR ANALYSIS OF MIXTURES OF NUCLEIC ACIDS AND METHODS FOR CONSTRUCTING THE SAME | Exiqon A/S (DK) | 2007-09-12 | — | — | EP | claimed |
| US-20060166238-A1 | Probes, libraries and kits for analysis of mixtures of nucleic acids and methods for constructing the same | EXIQON A/S (DK) | 2006-07-27 | — | — | US | claimed |
| WO-2006066592-A2 | PROBES, LIBRARIES AND KITS FOR ANALYSIS OF MIXTURES OF NUCLEIC ACIDS AND METHODS FOR CONSTRUCTING THE SAME | EXIQON A/S (DK) | 2006-06-29 | — | — | WO | claimed |
| US-20050227254-A1 | Quencher compositions comprising anthraquinone moieties | QIAGEN GMBH (DE) | 2005-10-13 | — | — | US | claimed |
| EP-1538154-A1 | Quencher composition comprising anthraquinone moieties | Exiqon A/S (DK) | 2005-06-08 | — | — | EP | claimed |
| US-20140227689-A1 | NOVEL METHODS FOR QUANTIFICATION OF MICRORNAS AND SMALL INTERFERING RNAS | EXIQON A/S (DK) | 2014-08-14 | — | — | US | disclosed |
| US-8383344-B2 | Methods for quantification of microRNAs and small interfering RNAs | EXIQON A/S (DK) | 2013-02-26 | — | — | US | disclosed |
| US-8192937-B2 | Methods for quantification of microRNAs and small interfering RNAs | EXIQON A/S (DK) | 2012-06-05 | — | — | US | disclosed |
| EP-1735459-B1 | METHODS FOR QUANTIFICATION OF MICRORNAS AND SMALL INTERFERING RNAS | EXIQON AS (DK) | 2012-01-25 | — | — | EP | disclosed |
| US-20110076675-A1 | NOVEL METHODS FOR QUANTIFICATION OF MICRORNAS AND SMALL INTERFERING RNAS | EXIQON A/S (DK) | 2011-03-31 | — | — | US | disclosed |
| US-7504495-B2 | Quencher compositions comprising anthraquinone moieties | EXIQON A/S (DK) | 2009-03-17 | — | — | US | disclosed |
| EP-1538154-B1 | Quencher composition comprising anthraquinone moieties | EXIQON AS (DK) | 2008-12-31 | — | — | EP | disclosed |
| US-5332521-A | Ferroelectric liquid crystal composition, liquid crystal optical device produced by using the ferroelectric liquid crystal composition, and method of producing the liquid crystal optical device | IDEMITSU KOSAN CO., LTD. (JP) | 1994-07-26 | — | — | US | disclosed |
| EP-0352637-B1 | Ferroelectric liquid crystal composition, liquid crystal optical device produced by using the ferroelectric liquid crystal composition, and method of producing the liquid crystal optical device | IDEMITSU KOSAN CO (JP) | 1994-03-30 | — | — | EP | disclosed |
| US-5200108-A | Flexible substrates supporting layer of liquid crystal material and non-liquid crystalline polymer | IDEMITSU KOSAN CO., LTD. (JP) | 1993-04-06 | — | — | US | disclosed |
| EP-0352637-A2 | Ferroelectric liquid crystal composition, liquid crystal optical device produced by using the ferroelectric liquid crystal composition, and method of producing the liquid crystal optical device | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1990-01-31 | — | — | EP | disclosed |
| US-4702561-A | AMINOANTHRAQUINONE BISANIL | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1987-10-27 | — | — | US | disclosed |
| EP-0002104-B1 | PLEOCHROIC DYES SUITABLE FOR USE IN SOLUTION WITH LIQUID CRYSTAL MATERIALS FOR ELECTRO-OPTIC DEVICE APPLICATIONS | BDH Chemicals Limited (GB) | 1982-10-20 | — | — | EP | disclosed |
| EP-0002104-A1 | Pleochroic dyes suitable for use in solution with liquid crystal materials for electro-optic device applications | BDH Chemicals Limited (GB) | 1979-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227254-A1 | Quencher compositions comprising anthraquinone moieties | ANXA5, SUN2, ANXA3 | TDP1 2732/4885APAF1 2128/4885MITF 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.